Companies developing new migraine therapies that inhibit calcitonin gene-related peptide (CGRP) or its receptor will test the first-in-class versus best-in-class struggle for market share over the next two years, as late-stage data are reported and applications for drug approvals are submitted.
Amgen Inc., as the only company that's reported Phase III data, is in the lead and plans to submit...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
